These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 18383442

  • 21. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 22. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 23. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; 2005 Apr; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

  • 24. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 25. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F, Schade R, Suissa S, Garbe E.
    Stroke; 2006 Jul 04; 37(7):1725-30. PubMed ID: 16728684
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    McGettigan P, Henry D.
    JAMA; 2006 Oct 04; 296(13):1633-44. PubMed ID: 16968831
    [Abstract] [Full Text] [Related]

  • 28. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 04; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 29. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 04; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 30. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y, Ducruet T, Boivin JF, Moore N, Perreault S, Zhao S.
    Arthritis Res Ther; 2005 Oct 04; 7(2):R333-42. PubMed ID: 15743481
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

  • 33. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 15; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 34. [Clinical pharmacology of the selective COX-2 inhibitors].
    Burian M, Geisslinger G.
    Orthopade; 2003 Dec 15; 32(12):1078-87. PubMed ID: 14655004
    [Abstract] [Full Text] [Related]

  • 35. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
    Health Technol Assess; 2008 Apr 15; 12(11):1-278, iii. PubMed ID: 18405470
    [Abstract] [Full Text] [Related]

  • 36. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L, Lee L, Weaver J, Bonnel R, Karwoski C, Governale L, Brinker A.
    Drug Saf; 2005 Apr 15; 28(10):917-24. PubMed ID: 16180941
    [Abstract] [Full Text] [Related]

  • 37. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.
    Am J Med; 2005 Nov 15; 118(11):1271-8. PubMed ID: 16271912
    [Abstract] [Full Text] [Related]

  • 38. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C, Wagner S.
    Clin Ther; 2003 Jan 15; 25(1):139-49. PubMed ID: 12637116
    [Abstract] [Full Text] [Related]

  • 39. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA.
    Lancet; 2004 May 29; 363(9423):1751-6. PubMed ID: 15172772
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.